HOOKIPA promotes Christine D. Baker to COO; base salary raised to $450,000

HOOKIPA Pharma Inc.

Baker, previously Chief Business Officer since Aug 2019, becomes COO effective May 1, 2022.
Base salary increased to $450,000; target annual incentive set at 40% of base salary.
She will continue to drive strategic collaborations and US operations growth.
CEO Joern Aldag cites her role in securing major pharma partnerships for the arenavirus platform.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Christine D. Baker

Chief Operating Officer

HOOK · HOOKIPA Pharma Inc.

Effective: 2022-05-01
Filed: May 2, 2022, 7:59 PM ET

On May 1, 2022, the Board of Directors (the “Board”) of HOOKIPA Pharma Inc. (the Company”) appointed Christine D. Baker as Chief Operating Officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christine D. Baker was appointed as Chief Operating Officer at HOOKIPA Pharma Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On May 1, 2022, the Board of Directors (the “Board”) of HOOKIPA Pharma Inc. (the Company”) appointed Christine D. Baker as Chief Operating Officer, effective immediately.

View on SEC.gov

HOOKIPA Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-054817

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.